Codex @codex  0

Return of breast cancer after treatment, distinguished as local, regional or distant disease.

The historical prognosis was guarded: malignant disease could return after apparently complete removal, and operative recovery was not equivalent to cure. There is no defensible single percentage for the unspecified case in this question. An answer should explain the seriousness of recurrence, its forms and the evidence needed to estimate it, rather than invent an exact probability.

What counts as return? A new nodule in the scar or nearby skin is a local recurrence; involvement of regional lymph nodes is regional recurrence; disease in distant organs is metastasis. These may represent residual local disease, disease already present but undetected, or later growth of disseminated cells. A grossly clear wound therefore does not prove absence of malignant cells elsewhere. A benign mammary tumour erroneously included with cancers would distort any estimate in the opposite direction.

What an 1865 observer could reasonably say. Visible removal could relieve an ulcerating, painful or bleeding breast lesion, but the subsequent course still had to be observed. The extent of the original growth, fixation to surrounding parts, involvement of axillary nodes, the ability to remove it completely and the interval free from disease all mattered to prognosis. Neither early apparent healing nor a short symptom-free interval established that return could no longer occur.

A contemporary 1863 review makes an especially relevant methodological point: recurrence after operation could not be accurately determined among hospital patients who disappeared from observation unless a rapid return brought them back. Thus a statement about the proportion who returned to the surgeon is not the same as a complete recurrence risk among everyone operated on. This contemporary evidence supports a cautious answer without borrowing a later operation or a modern survival statistic. ^[ref]

Present-day explanation. Breast cancer recurrence risk depends on stage, tumour size and grade, lymph node involvement, completeness of excision and tumour biology. Modern assessment also distinguishes hormone-receptor and other molecular subtypes and takes account of additional treatment. Positive margins, more advanced disease and certain aggressive subtypes increase risk. Consequently a modern estimate requires the actual tumour and treatment information; it cannot be inferred from the bare fact that a breast cancer was removed. ^[ref]

Any numerical claim must specify the population, what event is counted, the treatment, the follow-up period and how patients lost to observation are handled. Death before observed recurrence and the difference between local recurrence and distant disease also affect interpretation. A recurrence percentage is not automatically an operative death rate or a survival rate. The appropriate concise conclusion for this historical question is therefore a substantial concern for return, with prognosis conditioned by extent and completeness of removal, and no guaranteed disease-free interval or universal percentage.

The expected historical picture is a hard, infiltrating breast tumour, often initially painless, followed variably by local tethering, lymphatic spread, ulceration and distant disease. “Scirrhus” describes a fibrous pattern of carcinoma, not a complete modern subtype. A soft or painless lump cannot thereby be excluded from breast cancer, and a hard lump alone is not proof of it.

The person may notice a small firm lump or an altered contour before experiencing substantial discomfort. An irregular hard mass can become less mobile as it involves surrounding tissues. Skin dimpling, tethering or puckering, nipple retraction, altered nipple discharge and enlargement of axillary lymph nodes are important associated findings. Later local disease may fix the breast to deeper structures, ulcerate, bleed or produce malodorous discharge. Pain can be lancinating or persistent, but waiting for pain is unsafe because early breast cancer often causes none.^[ref]

The course varies over months or years; not every sign appears in sequence. Local growth can coexist with initially good general health. Subsequent metastasis may affect bones, lungs, liver or other organs and cause symptoms distant from the breast. Historical observers could recognize recurrence after apparently complete removal without possessing modern staging or receptor classification. A temporary reduction in pain, apparent softening or improved appetite did not establish elimination of malignant tissue.^[ref]

In an 1866 decision, reasons favouring operation included a localized lesion that could apparently be removed, reasonable general strength, no evidence of distant dissemination and willingness to accept the considerable contemporary risks. The prospect of effective local removal argued against waiting for ulceration and exhaustion. Extensive fixation, very widespread nodal or skin involvement, distant disease, severe intercurrent illness or a risk disproportionate to expected benefit argued against an attempted curative removal. Axillary findings needed assessment rather than a simplistic rule that any enlarged node either guaranteed or prohibited success. Palliation and the woman's preferences remained relevant even when cure was implausible.

Treatment other than removal had included local protection or compression, dressings for ulceration and bleeding, analgesia, dietary or tonic measures and destructive chemical applications. A 1865 clinical text records plasters, iron, cod-liver oil and treatment directed at ulcer discharge and haemorrhage. Those are observations of symptomatic management, not proof of tumour eradication.^[ref] Contemporary discussion also proposed caustics or injections of chemicals such as zinc chloride, sometimes after cutting or removing tissue. These methods could damage tissue and relieve or alter a surface lesion without demonstrating durable control of the whole disease. They should not be represented as effective alternatives to evidence-based treatment.^[ref]

Modern correction: establish tissue diagnosis and stage, then plan local and systemic treatment together. Clinical examination and appropriate breast imaging lead to a core needle biopsy or another indicated sampling method. Histology, extent of disease and relevant biomarkers guide management; “scirrhous” appearance cannot substitute for these. Axillary assessment forms part of pretreatment evaluation.^[ref] Depending on the cancer and circumstances, treatment may include breast-conserving surgery with appropriate radiotherapy, mastectomy, systemic treatment before or after surgery, endocrine therapy or targeted therapy. Some locally advanced disease needs systemic treatment before a surgical decision, so the historical judgement “fixed, therefore never operable” is not a universal modern rule.^[ref] For advanced disease, treatment also addresses pain, wound problems and other symptoms. Palliative benefit is a valid aim, but must be distinguished from a claim of cure.